$5.63
+1.3%Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
IMA • NASDAQ
| ImageneBio Inc Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
800K | 3.5M | 9.2M | 15.6M | 31M | 9.2M | 13.8M | 990K | |
GROSS PROFIT | ||||||||
(1M) | (0.0) | (1M) | (64.3M) | (47.1M) | (44.8M) | (24.9M) | (39M) | |
-233K | 3.5M | 8.1M | -48.7M | -16.1M | -35.7M | -11.2M | -38M | |
OPERATING INCOME | ||||||||
(48.2M) | (40.5M) | (83.6M) | (22.2M) | (18M) | (8.9M) | (32.2M) | (41.5M) | |
(20.7M) | (8.4M) | (24.9M) | (22.2M) | (18M) | (8.9M) | (7.3M) | (2.9M) | |
(28.5M) | (32.1M) | (59.7M) | (64.3M) | (47.1M) | (44.8M) | (24.9M) | (38.6M) | |
-48.5M | -37M | -75.4M | -70.9M | -34.1M | -44.5M | -18.5M | -40.9M | |
PRE-TAX INCOME | ||||||||
2M | 7.4M | 7.1M | 2.1M | 23K | 0.0 | 0.0 | 0.0 | |
-1M | (0.0) | -1M | -64.3M | -47.1M | -44.8M | (0.0) | (0.0) | |
2.8M | 445K | 7.1M | 2.1M | 23K | 263K | 1.7M | 29K | |
-45.7M | -36.6M | -68.3M | -68.8M | -34.1M | -44.3M | -16.8M | -40.9M | |
NET INCOME | ||||||||
-350K | (13K) | -162K | (0.0) | (0.0) | (0.0) | (71.1K) | (0.0) | |
-45.3M | -36.6M | -68.2M | -68.8M | -34.1M | -44.3M | -16.8M | -40.9M |
IMA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 13, 2026 | April 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 12, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 17, 2026 | February 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 12, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 19, 2025 | November 19, 2025 | 2025 |
Continue your IMA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.